Literature DB >> 9891483

nm23-H1 protein expression in newly diagnosed and relapsed childhood acute lymphoblastic leukemia.

R Koomägi1, A Sauerbrey, F Zintl, M Volm.   

Abstract

In a retrospective study, immunocytochemistry was used to analyze the cells of 62 newly diagnosed and 28 relapsed childhood acute lymphoblastic leukemias (ALL) for the expression of nm23-H1 protein. Of the 62 newly diagnosed ALL, only 9 cases exhibited positive staining (15%) while 10 of the 28 relapsed ALL did (36%). This difference is statistically significant (P = 0.03, Fisher's exact test). Furthermore, the presence of mutations in the exons 1-5 was investigated by RT-PCR and single-strand conformation polymorphism (SSCP) analysis. No mutations could be detected in either the newly diagnosed or relapsed ALL. This finding suggests that nm23-H1 mutations may be a rare event in ALL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9891483

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

Authors:  Christopher J Ott; Nadja Kopp; Liat Bird; Ronald M Paranal; Jun Qi; Teresa Bowman; Scott J Rodig; Andrew L Kung; James E Bradner; David M Weinstock
Journal:  Blood       Date:  2012-08-17       Impact factor: 22.113

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.